

# **Molecular Screening of Glucose-6- Phosphate Dehydrogenase Deficiency Among *P. Falciparum* Infected Children in Kaduna North Local Government Area of Kaduna State**

## **Abstract**

Glucose 6 phosphate dehydrogenase deficiency (G6PD deficiency) is an inherited genetic disorder characterized by reduced or absent activity of the G6PD enzyme. It is prevalent globally, especially in regions where malaria is endemic. The G6PD enzyme plays a critical role in maintaining cellular redox balance and protecting red blood cells from oxidative stress. This study was conducted in Kaduna North Local Government Area aim to screen and identify G6PD deficiency among children aged 1-5 years. The study utilized several methods, including rapid diagnostic tests for detecting Plasmodium falciparum malaria, automated blood analyzers for measuring red blood cell parameters, quantitative G6PD kits to assess enzyme activity, and spectrophotometer assays. Among 207 children who tested positive for Plasmodium falciparum, 33 (15.94%) were identified with G6PD deficiency in the 1-5 years age group. The highest prevalence was observed in age group 5 (33.33%), while age groups 3 and 4 had the lowest prevalence (12.12%). Males had a higher prevalence (66.67%) compared to females (33.33%), with Barau Dikko Teaching Hospital reporting the highest prevalence rate (16.98%) among the hospitals studied. The study found that 70.21% of cases exhibited the lowest G6PD enzyme activity (0-4.4 range) U/g Hb, while 19.15% showed normal activity (4.5-13.5 range) U/g Hb, and 10.64% had activity above 13.5U/g Hb. Management strategies include avoiding factors that can trigger hemolysis and providing genetic counseling, particularly before administering drugs that could potentially trigger this condition. Understanding the genetic underpinnings and implementing appropriate management strategies are essential for effectively managing individuals affected by G6PD deficiency.

**Key words:** Glucose-6-phosphate dehydrogenase (G6PD), Malaria, Plasmodium falciparum, Children, Kaduna State, Nigeria

## **Introduction**

Glucose-6-phosphate dehydrogenase (G6PD) is a cytoplasmic enzyme found in all the cells, and it is responsible for the oxidation of glucose-6-phosphate to

6-phosphogluconolactone. This reaction also converts the coenzyme nicotinamide adenine dinucleotide phosphate (NADP) into its reduced form, NADPH. NADPH is crucial for the reduction of oxidized glutathione (GSSG) back to its reduced form (GSH) via the enzyme glutathione reductase. This process is vital for protecting blood cells from oxidative damage by neutralizing peroxides as well as other reactive oxygen species (Ley *et al.*, 2017).

Red blood cells (RBCs) are susceptible to damage from both external and internal oxidants. Consequently, any defects in glutathione metabolism or the hexose monophosphate pathway, such as those resulted from a deficiency or impaired function of the enzyme glucose-6-phosphate dehydrogenase (G6PD), compromise the RBCs' ability to defend against oxidative imbalance. This can result in hemolytic anemia of varying degrees of severity and neonatal hyperbilirubinemia, a significant contributor to neonatal mortality and morbidity (WHO, 1989; Tong *et al.*, 2020). Glucose-6-phosphate dehydrogenase (G6PD) deficiency, an X-linked inherited disease, is the most significant among these enzyme defects. In the 1950s, it was initially identified in black people, who exhibited varying susceptibility to hemolytic anemia following the primaquine administration for malaria treatment (Vulliamy *et al.*, 1992; Zhong *et al.*, 2018).

G6PD deficiency is currently the commonest inherited erythrocyte disorder in subtropical regions and Mediterranean countries (Luzzato *et al.*, 2018). Migration has played a role in spreading G6PD deficiency globally, resulting in varying prevalence among diverse ethnicity. The condition predominantly affects males with a single X chromosome carrying the deficient gene and females with two copies of the gene having decreased activity of enzyme. However, females diagnosed of Turner's syndrome and about 10% of those who are carriers could also experience hemolysis when exposed to substance that can triggers oxidative stress which include chemicals, medications, infections, or 'fava' beans (Amiwerro *et al.*, 2012).

The clinical outcomes of G6PD deficiency vary widely, from no symptoms to persistent hemolysis throughout life, depending on the remaining enzyme activity. Major

manifestations include drug-induced hemolysis, non-spherocytic hemolytic anemia, favism, and severe, prolonged neonatal jaundice that can lead to neurological complications or mortality (Luzzatto *et al.*, 2020).

About 80% of preterm neonates and over 60% of full-term neonates exhibit clinical jaundice, characterized by elevated serum total bilirubin levels, in the first week of life (Wong *et al.*, 2017). Jaundice in G6PD-deficient neonates is influenced by various factors, including delayed maturation of liver enzymes needed for bilirubin processing and elimination. Additional contributors include neonatal immaturity, feeding methods, infections presence, and exposure to environmental substances like naphthalene-containing mothballs, herbal remedies, or antiseptic powders used on the umbilical cord (Dallol *et al.*, 2012; Cappellini *et al.*, 2022).

Hyperbilirubinemia resulting from G6PD deficiency can manifest from the first day of life and is often serious with long duration. While closely monitored cases rarely result in mortality, managing hyperbilirubinemia remains challenging in resource-limited settings, posing risks of severe neurological complications linked to toxicity of bilirubin (Dallol *et al.*, 2012; Wong *et al.*, 2017). In the United States, G6PD deficiency affects 1.6% of females and 2.5% of males, with most cases being moderately severe. Particularly affected are the African American males, showing a prevalence of around 10% in the population generally and 22.5% among jaundiced newborns. The deficiency prevalence reaches 70% in Kurdish Jews, 5% in China, within the range of 3% and 6.9% in Southern Russia and Pakistan, and drops to 0.1% in Japan (Lai *et al.*, 2017; He *et al.*, 2018). In West Africa, the prevalence of G6PD deficiency is in variation based on the specific region.

The prevalence of G6PD deficiency in Nigeria varies between 4% and 26%, with approximately 20% to 26% of the male population being affected (Piel *et al.*, 2013; Tetrad *et al.*, 2017). This is supported by 20% prevalence rates in Jos North Central and 14.4% in Sokoto, North West Nigeria have been reported. (WHO, 1989; Isaac *et al.*, 2013). The prevalence of G6PD deficiency among jaundiced newborns in Nigeria, influenced by the method of enzyme assay utilized, usually within the range of 20.5%

and 35.3%. This rate is notably higher compared to Americans of African descent (Egeseiet *et al.*, 2008).


## **Materials and Methods**

### **Study design**

In 207 children ages 1 to 5 years, this study sought to determine the prevalence of G6PD deficiency among those who were admitted or presented with *Plasmodium falciparum* malaria at selected hospitals between September and November of 2022. After counselling, parents or guardians gave their written, informed consent. The Ministry of Health in Kaduna State, Nigeria's Health Research Ethical Committee (HREC) gave ethical permission.

### **Study Area**

The study was conducted in Kaduna North Local Government Area of Kaduna State (Figure 1). It is located between latitude 10:35 North and longitudes 7:25 East. It is boarded by Igabi Local Government to the South, West and East of Kaduna State. It is characterized by two weather regimes. During the rainy season, the weather is warm, oppressive, and often overcast, while the dry season is characterised by hot weather with partly cloudy skies. From the beginning to the end of the year, temperatures usually in the range of 55°F to 95°F, rarely dropping below 50°F or exceeding 102°F. The state's natural vegetation consists largely of guinea savanna-characterised woodlands. (Sati *et al.*, 2020)



**Figure 1:** Map of Kaduna North Local Government Area Showing Sampling Sites

### Sample Collection Method

Following the Plasmodium falciparum Rapid Test Device screening for malaria parasites, a laboratory technician extracted 2.0 ml of venous blood from every kid in the study population who tested positive for malaria at the designated hospitals. In order to perform a G6PD deficiency screening using the BioSystem Quantitative in vitro test (S.A Costa Brava 30, 08030 Barcelona (REF code: 571), the samples were collected in EDTA (Ethylene Diamine Tetra-acetic Acid) tubes and promptly transferred in an ice-cooler box to the Precision Biomedicals Laboratory (Yu *et al.*, 2021).

### Screening of samples

#### Screening of Malaria Falciparum

The diagnosis of malaria was performed using the FIRST RESPONSE Malaria pf (HRP2) Ag rapid diagnostic test (RDT) kit. The assessment was performed following the manufacturer's instructions. To perform the test, a blood sample of 5  $\mu\text{L}$  was collected using the provided specimen transfer device and added to the "1" well of the cassette in the test kit. Then, two drops (60  $\mu\text{L}$ ) of the buffer solution were added to the "2" well. The test cassette was allowed to develop for 20 minutes (Alba *et al.*, 2021).

### **Determination of Red Blood Cell and Hemoglobin**

The RBC count and hemoglobin content of the samples were determined using automated techniques. Sysmex percentage absolute counting and Sysmex CyFlow Counting were used. (Ana-Maria *et al.*, 2020).

### **G6PD Enzyme Detection Using Test Kits**

The G6PD assay was conducted using the BioSystem (S.A Costa Brava 30, 08030 Barcelona (REF code: 571) based on the reaction principle described by Beutler. In this assay, NADPH is produced from NADP<sup>+</sup>, and the spectrophotometric measurement of NADPH at 340 nm was used to determine G6PD activity. A G6PD kit was obtained from Fortress Diagnostics (with product code BXC0571). The kit functions on the reaction principle described by Beutler, in which NADPH is produced from NADP<sup>+</sup>. The NADPH produced is measured spectrophotometrically at 340 nm. The assay was conducted following the manufacturer's protocol. Initially, 0.2 mL of whole blood was washed three times with 2 mL aliquots of 0.9% solution of NaCl and spun at 3,000 rpm for 10 minutes each time. The washed RBCs were then suspended in 0.5 mL solution of digitonin and left to stand at 4°C for 15 minutes before being centrifuged again. The resulting supernatant was incubated with substrate and cofactor at 37°C for 10 minutes in an electric oven. Subsequently, the mixture was analysed using an ultraviolet/visible spectrophotometer for the enzyme assay, which was performed within 2 hours of preparation. G6PD activity was quantified and expressed in international units per gram of haemoglobin (IU/g Hb), as described by Benedikt *et al.* (2017).

**Calculation:**

G6PD (IU/g Hb)= G6PD activity derived from analyser (Mu / ML)

$$100 \times \text{Hb (g/Dl)}$$

Values  $\leq 4.4$  U/g Hb were considered deficient.

Values  $> 4.5$  were considered sufficient (normal)

To preserve the blood for haematological parameter measurement, G6PD enzyme assay, and malaria diagnosis, the collected blood was introduced into a labelled bottle containing the dipotassium salt of ethylenediaminetetraacetic acid (EDTA). EDTA is commonly used as an anticoagulant to prevent blood clotting and preserve the blood sample for laboratory analysis. The labelled bottle with the EDTA-treated blood sample was then prepared for further testing and analysis (Yu *et al.*, 2021).


**Statistical Analysis**

The data obtained from the study of spectrophotometric measurement of G6PD enzyme activity was analysed using descriptive statistics from Microsoft Excel 2017. The result evaluation of the data was based on the reference provided by the company 4.5-13.5 U/g Hb. Anything below the said range is referred to as deficient, and the result was presented in histogram, percentage and frequency distribution.

**Results****Overall Prevalence of *Plasmodium falciparum* Children Sampled in Selected Hospital in Kaduna North L.G.A.**

Figure 2 shows the overall prevalence of *Plasmodium falciparum* among the children sampled in the selected hospitals. Results shows that of the 207 children examined, 33 (15.94%) children were positive for *Plasmodium falciparum*. Out of these number, 22

(66.67%) were male while 11 (33.33%) were female.



**Figure 2:** Overall Prevalence of *Plasmodium falciparum* among Children Sampled in Selected Hospital in Kaduna North L.G.A.

### Prevalence of *Plasmodium falciparum* among Children Sampled Based on Age Groups

Table 1 shows the prevalence of *Plasmodium falciparum* among children sampled based on age. Results shows that the highest prevalence was observed among children age 5 years, this is followed by children age 2 years. The least prevalence was observed among children of age groups 3 and 4 years. Results is presented in Table 1.

**Table 1:** Prevalence of *Plasmodium falciparum* among Children Sampled Based on Age Groups

Age Group	Number Examined	Number of positive (%)
1	40	6 (18.18)
2	32	8 (24.24)
3	40	4 (12.12)
4	37	4 (12.12)
5	58	11 (33.33)

<b>Total</b>	207	33 (15.94%)
--------------	-----	-------------

**Prevalence of *Plasmodium falciparum* among Children Sampled Based on Gender.**

Prevalence of *Plasmodium falciparum* based on gender is presented in Table 2. Results shows that male had the highest prevalence of 66.67% compared to female with prevalence of 33.33%.

**Table 2: Prevalence of *Plasmodium falciparum* among Children Sampled Based on Gender.**

<b>Gender</b>	<b>Number Examined</b>	<b>Number Positive (%)</b>
<b>Male</b>	115	22(66.67)
<b>Female</b>	92	11(33.33)
<b>Total</b>	207	

**Prevalence *Plasmodium falciparum* among Children Sampled in Selected Hospitals.**

The prevalence of *Plasmodium falciparum* among children sampled in selected hospitals shows that Barau Dikko had the highest prevalence of 16.98% while other hospitals sampled had the least prevalence of 15.39%.Results is presented in Table 3.

**Table 3: Prevalence *Plasmodium falciparum* among Children Sampled in Selected Hospitals.**

<b>Hospital Sampled</b>	<b>Number Examined (%)</b>	<b>Number of Positive (%)</b>
<b>Barau dikko</b>	53 (83.02)	(9)16.98
<b>Badarawa</b>	52 (84.02)	(8)15.38
<b>Ungwan Rimi</b>	52 (84.02)	(8)15.38
<b>Kawo</b>	52 (84.02)	(8)15.38
<b>Total</b>	207	

### **Prevalence of G6PD Deficiency Based on the G6PD Enzyme Activity.**

The distribution of G6PD deficiency based on the activity of the G6PD enzyme is depicted in this assay; in Table 4, NADPH is produced from NADP<sup>+</sup>, and the spectrophotometric measurement of NADPH at 340 nm is used to determine G6PD activity. The data was evaluated based on reference ranges provided by the company 4.5-13.5 U/g Hb. The children's samples that fall less than the reference range 0-4.4 u/gHb were deficient with 33 samples, and it covered 70.21% of the overall 47 samples tested to be positive for malaria falciparum<sup>3</sup> within 4.5-13.5U/g Hb with 9 samples 19.15% of the positive samples and greater than 13.5 is also referred to be normal with five children's samples 10.64% samples making up the overall 47 samples.

**Table 4:** Prevalence of G6PD Deficiency Based on the G6PD Enzyme Activity from 0-13.5(U/g Hb)


<b>G6PD Enzyme Activity(U/g Hb)</b>	<b>Enzyme</b>	<b>Percentage (%)</b>
<b>0-4.4</b>	33	70.21
<b>4.5-13.5</b>	9	19.15
<b>&gt;13.5</b>	5	10.64
<b>Total</b>	47	

### **Results of Molecular Detection of Glucose-6-Phosphate Dehydrogenase Deficiency Genes.**

The visualization of bands at 300bp (Plate I) indicates the presence of wild type 202 (W1), while 422bp also infers wild type 376 as (W2).and also band viewed at 600bp indicates 202 MUTANT type (M1) with 800bp shows 376 MUTANT type as (M2) 4 samples with lower G6PDD enzyme activity was amplified.

## DNA Sequence Variation of G6PD A-202 M1 and NG-009015.2

In this study nonsynonymous polymorphism of variant of G6PD A-202: NG-009015.2 of M1 1years old male. Mutation was observed in the query sequence with reference to the subject. There was a deletion of c16416T, c16417A, c16429A, c16446T, c16447G, c16516C, c16515C, c16520C, c16549A, c16555G and substitutions at position c16430G>T, c16431A>T, c16437A>T, c16441C>T, c16452A>C, c16469A>T, c16475G>T, c16489T>C, insertion of G was also observed between position c16421 and c16422 and that of A at position c16447 and 16448. this leads to the change in amino acids that will be translated in position. c16417I>K, c16420Y>Q, c16423P>A, c16426T>P, c16429I>P, c16432W>K, c16530W>V, c16533L>A, c16536F>V, c16539R>P, c16542D>G c16545G>W, c16548L>P, c16557E>P . The only synonymous polymorphism is c16554P, c16551L, c16408K, c16410K, c16413K.



**Plate I:** Amplified PCR Products of G6PD 202 and 376 genes.

Legend

M1 =MUT TYPE202/600bp

M2=MUT TYPE 376/800bp

W1=WILD TYPE202/300bp

W2=WILD TYPE 376/422bp

M = molecular ladder

Bp = base pair

-v = negative control

**M1 MUT TYPE A and B 202.**

ACTTTCGGCAGAGGCCATCCCGGAACAGCCACCTGAGGGAGGGACAGTGT  
AACCAGTGCGGCAGAGTAGGACCAGGCCTGGCCCTGACGGGAGGTCACA  
GGGGAAAGTGGGGATACATTTACCTTTGGTGGGGCTTGCTTCTTCTTAATTG  
AATTTCCCTGTTTTCTCCTGAAACGGGGAATGTATAAATGCTGTGACCAAGC  
TACATACATCATCCTCCACCCTGAATCTCCTGGTCTTACTCTGATTACTACTG  
GGCCAACATGGTTTGGTTGCCTGATATACCTAAAAACCCCATCATTAGCTG  
AGGATGACCTCCATCCCTGACCCACAAAACCTATTCTAATCTCCTGCCTGCT  
CCCTCTAAACCTGAAAAACCTGTTCAAAAAACATTACCCACCATCTGCCA  
TGTGGCCCCTCCACTGCCCTGACACCTCCCGCTTACATTAGGAAGAAATG  
GCTGAAAAACTGGAATAATGTTCCCTTTCCTAAGGGGAAAAACCGGATATG  
CTTCTGCCCAAACACCTTCCTCATGTTTATGACCGTTCCCCCTCAAGA.

CAGAAGGCCATCCCGGAACAGCCACCTGAGGGCAGGGACAGCTGTAACCA  
GTGCGGGAGAGTAGGACCAGGCCTGTCCCTGGCGGGAGGTCACAGGGGC  
AGGGGGGACACACTTACCAGATGGTGGGGTATTTCTTCTTCTTGGCCAAAT  
TTCCCTGTTTTATCCTGAAAAGGGGGATGTAAAATGCTGCTGACACACCTA  
CATACATCATCCTCCACCCTTGATCTCCTGGTCCTACTCCTGATCACTACTGG  
GCCACAACATGGTTTGGTTGCCTGATATACCTAAAAACCCCATCATTAGCT  
GAGGAAGACCTCCGTCCCTGACCCACAAACCTATTCTAATCTCCTGCCTTC  
CCCCTCTAAACCTGAAAATTCTGTTCAAAAAACCATCTACCCCCCAATGC  
CATGTGCCCTTCACTGCCCTGACCTCTCCCGCTTACATTAGGAAAAAACAT  
GGCTCCCCAATATGGATTATATTCCCTTTCCTAAGGAGAAAAAGGGCCATAT

CTTCTGCCACAAAACGCCTTCTATGTTTATGACGTTCCCCCTCAA.

#### **M4 MUT TYPE 376**

GGTAGGAGGCTGCATCATCGTACTGGCCAGCCACATAGGAGTTGCGGGAA  
AAAGTCCTCCTGTTGACTTCTCCTCTGGGGTGGCCTGGGAGACACGGACA  
GACAGACACACGACGATGTCAGCCCCTCTTTTGTAGTCCGTGGTGTCTGCC  
CCAGGGGAGTGGAGGGTCTTCCCTGGAGGCCGGGAGGGGGCCCTAAATCAG  
TGTCCCCCCCACACTGGGTTCGCCCCATCTTACAGTCTGCACATCCAGAGG  
GAGGGAGGCCAAAGCAGCAGCACAACACTGCCCCAGGTGGGACCCCTGT  
GCCTTAGACAGAGGCCAATTTTACATATTTTACCTGGGAAAATACACTGGA  
AAATCTCTCTCCAAAATATGACACCCAACTATGATTGGGGGAGAAAACCCG  
AACACTGGAGGGGACCTGTGGGTCTGGTACGGGGTGGTAATGGGGGTC  
TCAAGGAATACCACACAGGGGGGGGGCTGGAAAGAGAACTCCCCGATG  
GGATGGGGGAAGCCCCCAACTGCCTTGGGGGCTTGTGAGATGGAAAACC  
GGGTGGGGGGAGGCCTCCCCCCCCCTGAAAGGTTCTCTCTTGGGAATCC  
CCACTGGAGGTGAGGCATACCCCAATGAAGTTGGTTTTTCGGTAAAGGTTCC  
GACACAAGCCCTGTAGAGGGCGGGCATGATCTACCCATGGGGGGGGGAAGA  
GGA

**Figure 3:** Sequence of G6PD M1: MUT 202 Male aged 1 and M4: MUT 376 Female aged 3.

#### **DNA Sequence Variation of G6PD B-202 M1 and NG-009015.2**

The other G6PD A-202 variant of M2 female exhibit a synonymous polymorphism despite the deletion of certain nucleotides at position c16201G, c16232C, c16234A, c16247G, c16249G, c16252G, c16254C, c16271C, c16281G, c16309A, c16346G, c16359G, c16362G, c1365G, c16373T, c16446T, c16449T, c16494C, c16515C. And substitution at position c16155A>G, c161556A>T, c1171A>T, c16172G>C,

c16173A>T, c16174G>C, c16175G>C, c16176A>C, c16181G>C, c16191C>A, c16192G>T, c16195A>T, c16198C>T, c16204C>A, c16216A>G, c16222C>A, c16227C>A, c16228T>A c16240G>C, c16241A>T, c16242G>A, c16256G>T, c16257A>T, c16272T>G, c16275C>T, c16301G>T, c16302A>C, c16311G>T, c16316T>C, c16317A>T, c16318G>C, c16320G>A, c16354G>T, c16355G>C, c16367T>A, c16370G>T, C16371T>A, c16373G>T, c16379C>A, c16383G>T, c16384G>C, c16385A>C, c16386G>T, c16388C>T, c16389G>T, c16390G>T ,c16397A>T, c16398C>T, c16400G>A, c16417A>T, c16489C>T, c16491G>A .and one insertion of G between position c16275 c16276.

Despite the level of substitution deletion and insertion the only mutation that lead to change in amino translation was observed in position c16399N>D and c16417K>I.all the other amino acid translated in the subject sequence was synonymous to that of the query sequence which are;c16496G,c16402L,c16405A,c16408K,c16411K,c16414K,c16420Y,c16423P,c16426T,c16429I,c16432W,C16530W,c16533W,c16536F,c16539F,c16545G,c16542D,c16548L,c16551L.

### **DNA Sequence Variation between G6PD A-376 M4 and NG-009015.2**

A nonsynonymous polymorphism of variant of G6PD A-376: NG-009015.2of M4 4years old female mutation was observed in the query sequence with reference to subject. There was deletion of some certain nucleotides like c16670G, c16680A, c16692C, c16693G, c16695A,

c16698G, c16702G, c16705G, c16728G, c16734A, c16736G, c16738G, c16740G, c16743G,

c16752G, c16753G, c16754G, c16755G, c16756C, c16757G, c16758G, c16759G, c16760G,

c16761C, c16762G, c16766G, c16772G, c16774G, c16797C, c16798G, c16837C, c16739A,

c16841G, c16842A, c16844G, c16876C, c16891C, c16892G, c16909G, c16918G, c16926G,

c16934G, c16945G, c16965C, c16987G, c17021C, c17025G, c17037A, c17049C,  
c17050C,

c17051G, c17052T, c17053G, c17054C, c17055C, c17056C, c17057C, c17065G,  
c17068G,

c17070C, c17076T, c17084A, c17087T, c17137T, c17140C, c17156A, ,  
c17160A,c17206G,

c17216A, c17223G, c17227C, c17256A, and substitution at position c16661G>T,  
c16662C>T,

c16665G>A, c16672A>C, c16675T>G, c16683T>C, c16710T>C, c16711G>C,  
c16714G>A,

c16729G>C, c16746G>A, c16768G>C, c16829A>T, c16854C>G, c17211T>A,  
c16750A>T.

This scenario leads to the change in amino acid that will be translated in position  
c17207S>L,

c17210K>T, c17213G>K, c17216G>E, c17219L>D, c17222F, c17231A>R,  
c17234T>N,

c17237P>S, c17240M>Y, c17243W>V, c17246L>A, c17249A>G, c17252S>Q,  
c17255T>Y,

c17258M>D, c17261M>D, c17264Q>A, c17267P>A, c17270S>P, c17273T>Y.

The only synonymous polymorphism is c17189A, c17192T, c17195P, c17198E,  
c17201E,

c17204K, c17225F,

## **Discussion**

In the study, of the 207 children tested though the number of positive sample is small compared to other studies, but none the less, the overall prevalence of 33 (15.94%)

was recorded. In a related study, the findings of Isaac *et al.* (2013) also showed a lower prevalence (14.4%) of *Plasmodium falciparum* among children in Sokoto, North-West Nigeria. In contrast, the work of Egesie *et al.* (2008) revealed high prevalence (20%) of *Plasmodium falciparum* among children in Jos, North Central Nigeria.

The study also revealed high prevalence of *Plasmodium falciparum* among 5 years' age group compared to others, this could be due to the fact that the immune system of children can be compromised due to various factors which can make them more susceptible to infections and disease. Some of these factors are nutritional deficiency, congenital immune deficiency, environmental factors and medications. The study shows that male had high prevalence of *Plasmodium falciparum* (66.67%, 22 out of 33) out of 207 compared to females (33.33%, 11 out of 33). this may be as a result of the fact that more males were sampled at the course of sample collection than females. This finding is in agreement with the work of Abdulsalami *et al.*, (2016) where males (59.57%) had high prevalence than female (40.43%) in Katsina State, Nigeria. Contrary, the work of Shenkutie *et al.*, (2022) showed that *Plasmodium falciparum* is prevalent among females (4.8%) compared to the male (2.8%). Higher prevalence (16.98%) of *Plasmodium falciparum* was observed in Barau Dikko teaching hospital compared to the other hospitals. This could be due to several factors like demographic of the population and geographic location.

This study also revealed that children that were positive for *Plasmodium falciparum* had lower G6PD enzyme activity and falls within the range of 0-4.5 U/g HB, with 33(70.21%) others falling within the range of 4.5-13.5 U/g HB 9(19.15%) and > 13.5 U/g 5(10.64%). The World Health Organization classification of G6PD deficiency falls into five variants depending on the extent of enzyme activity and the seriousness of hemolytic response triggered by oxidative imbalance. Classes I to III exhibit enzyme deficiencies that lead to hemolysis, class IV represents the "wild type" with normal enzyme function, and class V is characterised by increased activity of the enzyme. Consequently, only the first three classes are deemed clinically significant. Class I (<10

of normal activity of the G6PD) with persistent non-spherocytic hemolytic anaemia, Class II (<10% of the normal activity of G6PD) without persistent non-spherocytic hemolytic anaemia, Class III (10-60% of normal activity) it is inherited condition that affects the RBCs it also indicate a partial impairment of the enzyme function, Class IV (60-100% normal activity) it is inherited condition that affects the RBCs it also indicate minimal or no impairment of the enzyme's function and Class V (>200% of normal activity G6PD) is said to be not recognised within the standard system for G6PD Deficiency because it is characterised by reduced or deficient activity only (Shenkutiet al ., 2022) this shows why most of the positive samples has lower G6PD enzyme activity because of the highest prevalence obtained within the range of 0-4.5 U/g HB with 33(70.21%) in this study.

This study identified the prevalence of G6PD deficiency among children with *Plasmodium falciparum* in Kaduna North. Malaria-endemic countries pose a significant challenge to the prevalence of malaria in glucose-6-phosphate dehydrogenase deficiency individuals. The mechanism of *Plasmodium falciparum* malaria resistance in people with G6PD deficiency is thought to be linked to impaired antioxidant defense, resulting in membrane damage in the early stages of parasitised red blood cells. This triggers a rapid removal of the parasites by phagocytosis, preventing their further development (Barisic *et al.*, 2005). The geographical malaria distribution corresponds closely to the deficient distribution of G6PD variants (Louicharoenet al., 2009).

Worldwide, a high frequency of infection occurs in malaria-endemic areas. As a result, it has been claimed that G6PD deficiency may offer a natural defense against malaria infection (Gampioet al., 2019; Sulistyaningrumet al., 2020; Awab et al., 2021). However, some studies have reported varying rates of G6PD deficiency in some parts of Nigeria. For instance, 14.4% of cases have been reported in Sokoto, North-West Nigeria. Isaac et al. (2013) and Egesieet al. (2008) have also made known a 20% prevalence in Jos, North Central, of Nigeria.

The findings in this study correlate with the previous prevalence of G6PD deficiency

studies, which show a wide geographical distribution, ranging from very rare among indigenous populations of Northern Europe to over 20% in portions of Southern Europe and Asia, and up to 40% in some areas of Southeast Asia, Africa, and the Middle East (Depina *et al.*, 2020). In recent years, a case-control study involving over 2,000 African children conducted by (Chu *et al.*, 2017) demonstrated a notable decrease in the risk of contracting malaria among individuals with the African form of G6PD deficiency, ranging from 46% to 58%. The research proposed that the evolutionary benefit of malaria resistance was counter balanced by the drawbacks associated with insufficient levels of G6PD. This helped to keep the number of malaria cases stable in areas where it is common (Chu *et al.*, 2017).

The actual mechanism behind this protective effect is yet to be fully understood, but two proposed explanations exist. The first suggestion revolves around the fact that malaria-causing parasites can only thrive in environments with low levels of oxygen (Arun *et al.*, 2023). This susceptibility to oxidative stress makes these parasites vulnerable. In the pentose phosphate pathway of RBCs, the glucose-6-phosphate dehydrogenase (G6PD) enzyme plays a vital function in producing NADPH and reduced glutathione. This mechanism is crucial for the survival of RBCs. Reduced glutathione, generated through NADP<sup>+</sup> reduction, counteracts H<sub>2</sub>O<sub>2</sub> and converts it into harmless H<sub>2</sub>O, preventing oxidative stress within RBCs. Given that oxidative stress is a major agent in red blood cell disruption, these cells are shielded from this effect (Abdullateef *et al.*, 2021).

In this study, G6PD deficiency of Male M1 MUT TYPE 202 A, which has about 562 base pair's showed many forms of non-synonymous polymorphism this led to numerous changes in the amino acid translated and M1 MUT TYPE 202 B which also has about 559 base pair has more synonymous polymorphisms and fewer amino acid changes, M4 MUT TYPE 376 has non-synonymous polymorphisms and fewer amino acid changes it contains about 706 base pair. This observation corresponds with earlier reports emphasizing the importance of the patient's sex, with males being at greater risk of severe G6PD deficiency than females (Aung *et al.*, 2023).

This is due to hemizygous deficiency and relates to an X-linked recessive genetic disease characterised by decreased activities of G6PD enzyme. This indicates that it primarily affects males because the X chromosome bears the G6PD gene. Consequently, males inherit G6PD deficiency from female carriers, who possess a copy of the primary gene on one of their X-chromosomes. While males with one abnormal gene copy manifest the disorder, carrier females typically never display noticeable signs. However, the rarity of G6PD deficiency in females stems from the requirement for both gene copies to be mutated to lead to the disease. In contrast, males need one abnormal gene copy only for the disease to manifest.

Other studies on the gene of G6PD state that it is carried on the X-chromosome at band 28 of the distal arm (Xq28) in humans. It consists of 12 introns and 13 exons, spans 18.5 Kilobases, and has a GC-rich promoter region. There have been over 400 variants found in this gene (Lo *et al.*, 2019, Roper *et al.*, 2020), but currently, only 217 actual mutations are recognized (Naylor *et al.*, 1996, Luzatto *et al.*, 2014, NORD 2020). Most of these sudden changes are point mutations that take place in different regions of the gene. Some common mutations include S188F (Mediterranean mutation), C131G, G487A, and A376G. These mutations can either be polymorphisms, which have lesser clinical symptoms, or sporadic variants. The frequency of polymorphisms is greater than that of sporadic variants. Interestingly enough, some variants that result in G6PD deficiency offer defense against *Plasmodium falciparum*-caused malaria (Abdullateef *et al.*, 2021).

The entire genetic mutations of G6PD result in a decrease in enzyme stability. (Naylor *et al.*, 1996). The active G6PD enzyme exists as a homodimer or homotetramer. Most mutations in the gene lead to changes in the amino acid sequence, which affects stability by disrupting protein folding, particularly at the dimer interface. Mutations that change how the structural NADP molecule binds, essential for maintaining the enzyme's integrity, also contribute to decreased stability of the enzyme (Mason *et al.*, 2007). This observation has primarily been studied in the context of the African

variant (G6PD A-), revealing that it also prevents severe falciparum malaria infection (Chu *et al* 2017). In Africa, the G6PD c.202T allele, known as the A-haplotype, is the predominant cause of G6PD deficiency, affecting over 30% of males in certain populations (Pamba *et al.*, 2012).

Hence, when G6PD enzymes are deficient in erythrocytes, it can lead to the induction of oxidative stress. In this scenario, the production of GSH is impaired, and H<sub>2</sub>O<sub>2</sub> is not effectively converted into H<sub>2</sub>O, resulting in oxidative imbalance. Consequently, malaria parasites are believed to avoid residing within erythrocytes where their maturation occurs because these parasites are susceptible to oxidative stress (Richard, 2019). Moreover, under conditions of oxidative stress, both the cell and the parasite experience potassium loss, potentially leading to the mortality of the parasite (Isabell *et al.*, 2022).

The alternative explanation proposes that Plasmodium parasites consume NADPH and deplete levels of reduced glutathione (GSH) in red blood cells. This depletion is exacerbated in individuals with G6PD deficiency, intensifying oxidative damage within the red blood cells (Arun *et al.*, 2023).

## **Conclusion**

The study revealed a significant occurrence (15.94%) of G6PD deficiency among children with *Plasmodium falciparum* malaria who reside in Kaduna North, L.G.A. The findings consistently point to a high prevalence of G6PD deficiency in this population.

Among the children studied, *plasmodium falciparum* was notably more prevalent in males 22(66.67%) compared to females 11(33.33%). Additionally, a significant majority of G6PD deficiency cases (92.92%) occurred during early childhood, specifically between the ages of 1 and 5 years, with age 5 having a higher prevalence of about (33.33%). which falls within the range of 0-4.5 U/g HB with 33(70.21%). This could be influenced by the mutation of the G6PD Gene, leading to reduced

enzyme activity.

In this study, several mutations on G6PD M1 MUT TYPE A, B 202 and G6PD M4 MUT TYPE 376 were observed in different positions due to deletion insertion and substitution, which led to changes in amino acid and lack of the G6PD enzyme due to the change of the dimer interface of the enzyme.

Though the number of sample size is small it is recommended to increase the number of samples. The study has established the occurrence of G6PD Deficiency among *Plasmodium falciparum*-infected children in Kaduna North L.G.A with a higher prevalence in males (66.67%) than females (33.33%) and higher among age group 5 years compared to others.

The study has revealed several mutations deleterious of mostly G Nucleotides and in some polymorphic incidences A, C, and T.

A notable change in the amino acids translation shows mostly why there were changes in the homodimer of the active G6PD enzyme due to the mutation, and it could lead to disrupting the mutation and it could lead to disrupting the protein folding by altering the binding of structural NADP molecule.

### **Recommendations**

1. It is crucial to Understand G6P Dehydrogenase it function and deficiency by studying the enzyme function including the role of G6PD in the pentose phosphate pathway and its importance in protecting cells from oxidative stress. With how G6PD Deficiency Explore the genetic basis and clinical manifestations of G6PD deficiency, including its impact on red blood cells and its association with hemolytic anemia.
2. The present study shows that enzymatic activity alone may not accurately predict clinical outcomes and genotypic information must be considered.

3. Additional research is required to give a better understanding of the severity of the G6PD Deficiency by Utilizing advanced technologies by the use of bioinformatics tools to analyze genetic data and predict the effects of mutations on G6PD gene and its functions. Also, to employ cell and animal models to study the physiological effects of G6PD deficiency and test new treatments that will help in managing the symptoms.

### **Consent for Publication**

All authors declare that written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editorial office of this journal.

### **Ethical Approval**

Ethical approval was sought from Kaduna State Ministry of Health and Barau Dikko Teaching Hospital, Kaduna State University.

### **REFERENCES**

- Abdullateef, A., Olajide, R. A., Emmanuel, E., Bolanle, M. K., & Umaru, K. (2021). Changes in Antioxidants in the Brain of Fluoride-Treated Rats. *Asian Journal of Research in Medical and Pharmaceutical Sciences*, 41–48. <https://doi.org/10.9734/ajrimps/2021/v10i130157>
- Allison, A. C. (2002). The discovery of resistance to malaria of sickle cell heterozygotes. *Biochemistry and Molecular Biology Education*, **30**(5), 279-287.
- Alving A.S., Carson P.E., Flanagan C.L., and Ickes C.E., (September 1956). "Enzymatic deficiency in primaquine-sensitive erythrocytes". *Science*. **124**(3220):484–5.
- Amiwero, C., and Olatunji, P. (2012). Prevalence of G6PD deficiency in children presenting with jaundice in Ilorin, Nigeria. *International Journal of Biomedical*

*and Health Sciences* **8**:21-26

- Ana-Maria S., Geoffrey B., Janne C., Seán J., Costelloe and Giuseppe L. (2020) Managing hemolyzed samples in clinical laboratories *Critical reviews in clinical laboratory sciences* **57** (1), 1-21.
- Andy S., Xin Y.S., Siaw T.Y., Nor A.M., Lee P.C., and Hock H.C.(2002)The mystery of 'saturation gap' and falsely normal G6PD: a case of primaquine-induced haemolysis in *Plasmodium vivax* malaria infection *Clinical Royal College of physicians Edinburgh* .**51**:146-8
- Anstee D.J. (June 2010). "The relationship between blood groups and disease". *Blood.Journal* **115** (23): 4635–4
- Araoye, M.O. (2004) Sample Size Determination in Research Methodology with Statistics for Health and Social Sciences. *Nathadex Publishers, Ilorin*, 115-121.
- Arun K.A., Sumithra M., Maddali N.A., Fouzia A., Aby A., Biju G., and Eunice S.E. (2020) molecular Characterization of G6PD Deficiency:Report of *Three Novel G6PD Variants Indian Journal Hematology Blood Transfion***2**: 349–355.
- Aung, T.H., Suansomjit, C. and Tun, Z.M., Prevalence of G6PD deficiency and diagnostic accuracy of a G6PD point-of-care test among a population at risk of malaria in Myanmar. *Malaria Journal* **22**, 143.
- Bahr, T. M., Lozano C.M., Agarwal, A. M., Meznarich, J. A., Yost, C. C., Li, P., and Christensen, R. D. (2020). A novel variant in G6PD (c. 1375C> G) identified from a Hispanic neonate with extreme hyperbilirubinemia and low G6PD enzymatic activity. *Neonatology* **117**(4), 532-535.
- Baird K., (2015). "Origins and implications of neglect of G6PD deficiency and primaquine toxicity in *Plasmodium vivax* malaria". *Pathological Global Health*. **109** (3): 93–106.

- Baird, J.K. (2013). Evidence and implications of mortality associated with acute Plasmodium vivax malaria. *Clinical Microbiology Reviews*, 26(1), pp.36-57.
- Bancone G., Poe D.D., Gornsawun G., Htway P.P., Gilder M.E., Archasuksan L., Chotivanich K., McGready R., and Nosten F., (2024) Spectrophotometric values for glucose-6-phosphate dehydrogenase activity in two-to six-month-old infants on the Thailand-Myanmar border. *Wellcome Open Research* 9(7):273.
- Bancone, G., Chu, C. S., Chowwiwat, N., Somsakchaicharoen, R., Wilaisrisak, P., Charunwatthana P., Bansil Mc Gray S., Domingo GJ., and Nosten, F. H., (2015). Suitability of capillary blood for quantitative assessment of G6PD activity and performances of G6PD point-of-care tests. *The American journal of tropical medicine and hygiene*, 92(4), 818.
- Barišić, M., Korać, J., Pavlinac, I., Krželj, V., Marušić, E., Vulliamy, T., and Terzić, J. (2005). Characterization of G6PD deficiency in southern Croatia: description of a new variant, G6PD Split. *Journal of human genetics*, 50(11), 547-549.
- Belfield, K. D., and Tichy, E. M., (2018). Review and drug therapy implications of glucose-6-phosphate dehydrogenase deficiency. *The Bulletin of the American Society of Hospital Pharmacists*, 75(3), 97-104.
- Benedikt L., Mohammad S.A., James J., O'Donnell, Mohammad S.H., Mohammad Gola m Kibria, Nusrat Jahan, Wasif A Khan, Kamala Thriemer, Mark D Chatfield, Ric N Price and Jack S Richards (2017). A comparison of three quantitative methods to estimate G6PD activity in the Chittagong Hill Tracts, Bangladesh *Public Library of Science* 25(1)12
- Berg J.M., Tymoczko J.L., Stryer L., *Biochemistry*. New York: W. H. Freeman and Co; (2002).4:2
- Betke, K., Brewer, G. J., Kirkman, H. N., Luzzatto, L., Motulsky, A. G., Ramot, B. and Siniscalco, M. (1979) Standardization of procedure for the study of

glucose-6-phosphate dehydrogenase: report of a WHO Scientific Group. World Health Org. Techn. Rep. Ser. 366, *Royal College of Physicians Edinburgh* **15**: 155–162.

Beutler E., (2008). "Glucose-6-phosphate dehydrogenase deficiency: a historical perspective". *Blood*. **111** (1): 16–24.

Bhutani V.K., and Michel K., Michel C., Vamsee C., Beritil G., Jiarus K. (2015). Point-of-Care Quantitative Measure of Glucose-6-Phosphate Dehydrogenase Enzyme Deficiency *Pediatrics Journal*, 2015, **136**(5):1268–1275.

Bhutani, V. K., Kaplan, M., Glader, B., Cotten, M., Kleinert, J., and Pamula, V. (2015). Point-of-care quantitative measure of glucose-6-phosphate dehydrogenase enzyme deficiency. *Pediatrics*, **136**(5)1268-1275.

Bhutani, V. K., Zipursky, A., Blencowe, H., Khanna, R., Sgro, M., Ebbesen, F., and Lawn, J. E. (2013). Neonatal hyperbilirubinemia and Rhesus disease of the newborn: incidence and impairment estimates for 2010 at regional and global levels. *Pediatric research*, **74**(1), 86-100.

Bonilla, J. F., Sánchez, M. C., and Chuaire, L. (2007). Glucose-6-phosphate dehydrogenase (G6PD): Response of the human erythrocyte and another cells to the decrease in their activity. *Colombia Médica*, **38**(1), 68-75.

Boonyuen, U., Chamchoy, K., Swangsri, T., Saralamba, N., Day, N. P., and Imwong, M. (2016). Detailed functional analysis of two clinical glucose-6-phosphate dehydrogenase (G6PD) variants, G6PDViangchan and G6PDViangchan+Mahidol: decreased stability and catalytic efficiency contribute to the clinical phenotype. *Molecular genetics and metabolism*, **118**(2), 84-91.

Brito, M. A., Peixoto, H. M., Almeida, A. D., Oliveira, M.D., Romero, G. S., Moura-Neto, J. P. and Lacerda, M. D. (2016). Validation of the rapid test Carestart (tm) G6PD among malaria *vivax*-infected subjects in the Brazilian Amazon. *Revista da Sociedade Brasileira de Medicina Tropical*, **49**, 446-455.

- Burstein, R., Henry, N. J., Collison, M. L., Marczak, L. B., Sligar, A., Watson, S and Filip, I. (2019). Mapping 123 million neonatal, infant and child deaths between 2000 and 2017. *Nature*, **574**(7778), 353-358.
- Cappellini, M. D., and Fiorelli, G. (2008). Glucose-6-phosphate dehydrogenase deficiency. *The lancet*, **371**(9606), 64-74.
- Chanarin, I., Dacie, J. V., and Mollin, D. L., (1959). Folic-acid deficiency in haemolytic anaemia. *British Journal of Hematology*. **5**,245-256.
- Chen, T. L., Yang, H. C., Hung, C. Y., Ou, M. H., Pan, Y. Y., Cheng, M. L. and Chiu, D. Y. (2018). Impaired embryonic development in glucose-6-phosphate dehydrogenase-deficient *Caenorhabditis elegans* due to abnormal redox homeostasis induced activation of calcium-independent phospholipase and alteration of glycerophospholipid metabolism. *Cell death and disease*, **8**(1),2545-2545.
- Chiang, S. H., Fan, M. L., and Hsiao, K. J., (2008). External quality assurance programme for newborn screening of glucose-6-phosphate dehydrogenase deficiency. *Annals Academy Medical Singapore*, **37**(3), 84-7.
- Chu, C. S., Bancone, G., Moore, K. A., Win, H. H., Thitipanawan, N., Po, C and White, N. J. (2017). Haemolysis in G6PD heterozygous females treated with primaquine for *Plasmodium vivax* malaria: a nested cohort in a trial of radical curative regimens. *PLoS medicine*, **14**(2)1002224.
- Clement A.Y., Florence O.I., and Michael O.T. (2017) Diagnostic Test Kits Detection of Malaria Parasites among Pregnant Women Attending Antenatal in Selected Hospitals in Anyigba, Kogi State, Nigeria. *Advances in Bioscience and Biotechnology* **8**:8
- Dallol A., Banni H., Gari M.A., Al-Qahtani M.H., Abuzenadeh A.M., And Al-Sayes F. (2012). Five novel Glucose-6-Phosphate Dehydrogenase Deficiency

Haplotypes Correlating with Disease Severity. *Journal of Translational Medicine*; **10**:199-207.

DePina A.J., Pires C.M., Andrade A.J., Dia A.K, Moreira A.L., and Ferreira MC(2020).

The prevalence of glucose-6-phosphate dehydrogenase deficiency in the Cape Verdean population in the context of malaria elimination. *Public Library of Science* 15:0229574.

Djigo, O. K. M., OuldAhmedou Salem, M. S., Diallo, S. M., Bollahi, M. A., Boushab, B. M., Garre, A and Ould Mohamed Salem Boukhary, A. (2021). Molecular epidemiology of G6PD genotypes in different ethnic groups residing in Saharan and Sahelian zones of Mauritania. *Pathogens*, **10**(8), 931.

Domingo, G. J., Satyagraha, A. W., Anvikar, A., Baird, K., Bancone, G., Bansil, P and Von Seidlein, L. (2013). G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests. *Malaria journal* .**12**(391)

Egesie, O. J., Joseph, D. E., Isiguzoro, I., and Egesie, U. G. (2008). Glucose-6-phosphate dehydrogenase (G6PD) activity and deficiency in a population of Nigerian males resident in Jos. *Nigerian Journal of Physiological Sciences*, **23**(1-2).

Egube, B. A., Ofili, A. N., Isara, A. R., and Onakewhor, J. U. (2013). Neonatal jaundice and its management: knowledge, attitude, and practice among expectant mothers attending antenatal clinic at University of Benin Teaching Hospital, Benin City, Nigeria. *Nigerian journal of clinical practice*, **16**(2), 188-194.

Eugenia L.o., Daibin Z., Beka R., Kareen P., Cristian Koepfli, Ming-Chieh L., Delenasaw Y., and Guiyun Yan(2019). Prevalence and distribution of G6PD deficiency: implication for the use of primaquine in malaria treatment in Ethiopia. *Malaria journal* **18**(1-10).

Ezeaka, C. V., Ugwu, R. O., Mukhtar-Yola, M., Ekure, E. N., and Olusanya, B. O.

- (2014). Pattern and predictors of maternal care-seeking practices for severe neonatal jaundice in Nigeria: a multi-centre survey. *BMC Health Services Research*, **14**(1), 1-10.
- Farouk, Z. L., Muhammed, A., Gambo, S., Mukhtar-Yola, M., Umar Abdullahi, S., and Slusher, T. M. (2018). Follow-up of children with kernicterus in Kano, Nigeria. *Journal of tropical pediatrics*, **64**(3), 176-182.
- Filosa, S., Fico, A., Paglialunga, F., Balestrieri, M., Crooke, A., Verde, P. and Martini, G. (2003). Failure to increase glucose consumption through the pentose-phosphate pathway results in the death of glucose-6-phosphate dehydrogenase gene-deleted mouse embryonic stem cells subjected to oxidative stress. *Biochemical Journal*, **370**(3), 935-943.
- Flint, J., Harding, R. M., Boyce, A. J., and Clegg, J. B. (1998). 1 The population genetics of the haemoglobinopathies. *Baillière's clinical haematology*, **11**(1), 1-51.
- Gammal R.S., Pirmohamed M., Somogyi A.A., Morris S.A., Formea C.M., Elchynski A.L., Oshikoya K.A., McLeod H.L., Haidar C.E., Whirl-Carrillo M., (2023) Expanded clinical pharmacogenetics implementation consortium (CPIC) guideline for medication use in the context of G6PD genotype. *Clinical pharmacology; Therapeutic* **113**(5)973-985
- Gimenez, A.M., Marques, R.F., Regiart, M. and Bargieri, D.Y., (2021). Diagnostic methods for non-falciparum malaria. *Frontiers in Cellular and Infection Microbiology*, 11, p.681063.
- Goodman, O. O., Kehinde, O. A., Odugbemi, B. A., Femi-Adebayo, T. T., and Odusanya, O. O. (2015). Neonatal jaundice: knowledge, attitude and practices of mothers in Mosan-Okunola community, Lagos, Nigeria. *Nigerian Postgraduate Medical Journal*, **22**(3)158-163.
- Greco, C., Arnolda, G., Boo, N. Y., Iskander, I. F., Okolo, A. A., Rohsiswatmo, R., and Coda Zabetta, C. D. (2016). Neonatal jaundice in low-and middle-income

countries: lessons and future directions from the 2015 Don Ostrow Trieste Yellow Retreat. *Neonatology*, **110**(3)172-180.

He, M., Lin, K., Huang, Y., Zhou, L., Yang, Q., Li, S., and Jiang, W. (2018). Prevalence and molecular study of *G6PD* Deficiency in the Dai and Jingpo Ethnic Groups in the Dehong Prefecture of the Yunnan Province. *Human Heredity*, **83**(2)55–64.

He, Y., Zhang, Y., Chen, X., Wang, Q., Ling, L., and Xu, Y. (2020). Glucose-6-phosphate dehydrogenase deficiency in the Han Chinese population: molecular characterization and genotype–phenotype association throughout an activity distribution. *Scientific Reports*, **10**(1)17106.

Hedrick P.W., (October 2011). Population genetics of malaria resistance in humans. *Heredity Journal*. **107** (4): 283–304..

Iliyasu, Z., Abubakar, I. S., and Gajida, A. U. (2010). Magnitude and leading causes of in-hospital mortality at Aminu Kano Teaching Hospital, Kano, northern Nigeria: A 4-year prospective analysis. *Nigerian Journal of Medicine* **19**(4), 400-406.

Isaac, I. Z., Mainasara, A. S., Erhabor, O., Omojuyigbe, S. T., Dallatu, M. K., Bilbis, L. S., and Adias, T. C. (2013). Glucose-6-phosphate dehydrogenase deficiency among children attending the emergency paediatric unit of Usmanu Danfodiyo University Teaching Hospital, Sokoto, Nigeria. *International Journal of General Medicine* **6**:557-562.

Isabell B., Satyamaheshwar P., Kim C.H., Kristina H., Patrick M., Palak G., Janina P., Mahsa R., Oleksii S., Elena V., Daniela U., Luigi F.S., Kathrin B., Michael P. Hedrick., Paul H., Thomas D. Y. Chung , b Michael R. Jackson , b Evelin Schwarzer , e Stefan R., a Lars Bode , c Katja B., and Anthony B.P. (2022)An Optimized DihydrodibenzothiazepineLeadCompound (SBI-0797750) as a Potent and SelectiveInhibitor of *Plasmodium falciparum* and *P.vivax*Glucose 6-Phosphate Dehydrogenase 6-Phosphogluconolactonasey *Antimicrobial Agents Chemotherapy* **66**(4):

02109-21.

- Jallow M., Teo Y.Y., Small K.S., Rockett K.A. (2009). "Genome-wide and fine-resolution association analysis of malaria in West Africa". *National Genetics Journal* **41**(6): 657–665.
- Kwiatkowski D.P., (August 2005). How malaria has affected the human genome and what human genetics can teach us about malaria. *American Journal of Human Genetics*. **77** (2): 17
- Lai, S. , Li, Z., Wardrop, N. A., Sun, J., Head, M. G., Huang, Z., Zhou, S., Yu, J., Zhang, Z. , Zhou, S.□S. , Xia, Z. , Wang, R. , Zheng, B. , Ruan, Y. , Zhang, L. I. , Zhou, X.□N., Tatem, A. J., and Yu, H. (2017). Malaria in China, 2011–2015: An observational study. *Bulletin of the World Health Organization*, **95**(8), 564–573.
- Ley, B., Bancone, G., and von Seidlein, L. (2017). Methods for the field evaluation of quantitative G6PD diagnostics: a review. *Malaria Journal* **16**, 361.
- Lo, E., Zhong, D., Raya, B., Pestana, K., Koepfli, C., Lee, M. C., and Yan, G. (2019). Prevalence and distribution of G6PD deficiency: implication for the use of primaquine in malaria treatment in Ethiopia. *Malaria journal*, **18**(1), 1-10.
- Longo L., Vanegas O.C., Patel M, Rosti V., Li H., Waka J., Merghoub T., Pandolfi P.P., Notaro R., Manova K., and Luzzatto L.(2002) Maternally transmitted severe glucose 6-phosphate dehydrogenase deficiency is an embryonic lethal. *European Molecular Biology Journal* ,**15**;21(16):4229-39
- Louicharoen C., Patin E., Paul R., Nuchprayoon I., Witoonpanich B., Peerapittayamongkol C., Casademont I., Sura T., Laird N.M., Singhasivanon P., Quintana-Murci L., and SakuntabhaiA(2009). Positively selected G6PD-Mahidol mutation reduces *Plasmodium vivax* density in Southeast Asians. *Science.Journal*; **326**(5959):1546-9.
- Luzzatto L., Ally M., and Notaro R. (2020) Glucose-6-phosphate dehydrogenase

deficiency. *Blood*. 2020 ;**136**(11):1225-1240.

Luzzatto L., and Arese P., Favism (2018) Glucose-6-Phosphate Dehydrogenase Deficiency. *New England Journal of Medicine*. 2018 Jan 4;378(1):60-71..

Luzzatto, L., and Seneca, E. (2014). G6 PD deficiency: a classic example of pharmacogenetics with ongoing clinical implications. *British journal of haematology*, **164**(4), 469-480.

Maltha, J., Gillet, P., and Jacobs, J. (2013). Malaria rapid diagnostic tests in travel medicine. *Clinical Microbiology and Infection*, **19**(5), 408-415.

Maria A., Sierra, Qianhao Li., Smruti Pushalkar, Bidisha Paul,1 Tito A., Sandoval, Angela R., Kamer, Patricia C., Yuqi G., Ryan R.R., Alexander V. Alekseyenko, Xin Li., and Deepak S.,(2020). The Influences of Bioinformatics Tools and Reference Databases in Analyzing the Human Oral Microbial Community, *Genes (Basel Journal)*. **11**(8): 878.

Mason P.J., Vulliamy T.J., and Mehta A Glucose-6-phosphate dehydrogenase (G6PD) deficiency Best Practice and Research *Clinical Heamatology***13**(1)21-36.

Mason, P. J., Bautista, J. M., and Gilsanz, F. (2007). G6PD deficiency: the genotype-phenotype association. *Blood Reviews*, **21**(5), 267-283.

Nantakomol D., Paul R., Palasuwan A., Day N.P., White N.J., and ImwongM.(2013) Evaluation of the phenotypic test and genetic analysis in the detection of glucose-6-phosphate dehydrogenase deficiency. *Malaria Journal*.**12**:289.

Naylor, C. E., Rowland, P., Basak, A. K., Gover, S., Mason, P. J., Bautista, J. M., and Adams, M. J. (1996). Glucose 6-phosphate dehydrogenase mutations causing enzyme deficiency in a model of the tertiary structure of the human enzyme *Blood Journal* .**87**(7):2974-82

Newton, C. R., Warn, P. A., Winstanley, P. A., Peshu, N., Snow, R. W., Pasvol, G., and Marsh, K. (1997). Severe anaemia in children living in a malaria endemic area of Kenya. *Tropical medicine and international health*, **2**(2), 165-178.

- Nicholas M.D., Kim A.P, Angela R., Benedikt L., Nicholas M.A., and Ric N.P. (2023) Primaquine-induced Severe Hemolysis in the Absence of Concomitant Malaria: Effects on G6PD Activity and Renal Function *American Journal of Tropical Medical Hygiene*, **108**(1): 76–80.
- Noori-Dalooi M.R., Hajebrahimi Z., and Najafi L, (2007). A comprehensive study on the major mutations in glucose-6-phosphate dehydrogenase-deficient polymorphic variants identified in the coastal provinces of Caspian Sea in the north of Iran. *Clinical Biochemistry Journal*, **40**(9-10):699–704.
- Norunaluwar J., Raja Z.A., Emida M., Azlin I., Hafiza A., Siti B., and Ainoon O. (2016) *Evaluation of Glucose-6-Phosphate Dehydrogenase stability in stored blood samples* **15**:155-162
- Notaro R. and Afolayan A., and Luzzatto L., (2000). Human mutations in glucose 6-phosphate dehydrogenase reflect evolutionary history. *FASEB journal : official publication of the Federation of American Societies for Experimental Biology journal*. **14**. 485-94.
- Noymi B., Dipankar B., Paresh K.S, and Jatin S. (2024). Identification of glucose-6-phosphate dehydrogenase variants by utilizing polymerase chain reaction–Restriction fragment length polymorphism based method *Gene Reports* **35**:101911.
- Oduola T., Adeosun G, Ogunyemi E, Adenaike and Bello A. (2005) A. Studies on G6PD stability in blood stored with different anticoagulants. *The Internet Journal of Hematology*. **2**:2.
- Ogunlesi, T. A., and Abdul, A. R. (2015). Maternal knowledge and care. Seeking behaviors for newborn jaundice in Sagamu, Southwest Nigeria. *Nigerian journal of clinical practice*, **18**(1), 33-40.
- Okafor, I. M., Mbah, M., and Usanga, E. A. (2012). The impact of anaemia and malaria parasite infection in pregnant women, Nigerian perspective. *IOSR Journal of*

- Olusanya, B. O., Kaplan, M., and Hansen, T. W. (2018). Neonatal hyperbilirubinaemia: a global perspective. *The Lancet Child and Adolescent Health*, **2**(8), 610-620.
- Olusanya, B. O., Osibanjo, F. B., Mabogunje, C. A., Slusher, T. M., and Olowe, S. A. (2016). The burden and management of neonatal jaundice in Nigeria: a scoping review of the literature. *Nigerian Journal of Clinical Practice*, **19**(1), 1-17.
- Oyediji S.I., Odoh I.M., Ojerinde A.O, and Awobode H.O. (2020). Investigation of the sequence profile of the Plasmodium falciparum 18SrRNA diagnostic target in isolates from naturally infected children with uncomplicated malaria, Genes (Basel). *Nigerian Journal of Parasitology***42**(2) 11(8): 878.
- Pal S., Myburgh J., Bansil P., Hann A. and Robertson L., (2021) Reference and point-of-care testing for G6PD deficiency: Blood disorder interference, contrived specimens, and fingerstick equivalence and precision. *Public Library of Science* **16**(9)0257560.
- Pamba A, Richardson N.D, Carter N., Duparc S., Premji Z., Tiono A.B., and Luzzatto L.( 2012) Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone. *Blood Journal***120**(20):4123-33
- Piel F.B., Howes R.E., Nyangiri O.A., Moyes C.L., Williams T.N., Weatherall D.J., and Hay S.I.(2013). Online biomedical resources for malaria-related red cell disorders. *Human Mutation Journal*,**34**(7):937–944.
- Purnima R., Chandan N.,Anirban D., Ishita M., Nalini S., Bhupen B., Chubalemia L.K.G., Lynrah D.S., and Alice R. (2020).*Study of Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency and Genotype Polymorphism of G6PD B and G6PD (A+/A-) in Patients Treated for Plasmodium vivax Malaria in a Tertiary Care Hospital in North East India.**Cureus Journal*, **12**(11)11463
- Rati D.,Vinodkumar G., Rajasubramaniam S., Singh M.P.S.S., Purushottam P,

- Neena V., Neelima M., Naseem A., S.L. Hoti, Harsha V. Hegde, Prashant W., Ashish C., Prabhakar K., Pramod M., Malay and Mukherjee B. (2020). Prevalence and spectrum of mutations causing G6PD deficiency in Indian populations, *Infection Genetics Evolution Journal*. **86**:104597
- Roper, D. R., Dela S.B., Soni, V., Fletcher, K., and Green, J. A. (2017). Abrogation of red blood cell G6 PD enzyme activity through Heat treatment: development of survey material for the UK NEQAS G6PD scheme. *International Journal of Laboratory Hematology*, **39**(3)308-316.
- Roper, D., Layton, M., Rees, D., Lambert, C., Vulliamy, T., De la Salle, D Souza C; British Society for Haematology. (2020). Laboratory diagnosis of G6PD deficiency. A British Society for Haematology Guideline. *British Journal Haematology Guideline*; **189**(1)24-38.
- Sampa P., Pooja B., Germana B., Sevan H., Maria K., Gornpan G., PimsupahPenpitchaporn, C.S., Chu, François N., and Gonzalo J. (2019). Evaluation of a Novel Quantitative Test for Glucose-6-Phosphate Dehydrogenase Deficiency: Bringing Quantitative Testing for Glucose-6-Phosphate Dehydrogenase Deficiency Closer to the Patients *American Journal of Tropical Medicine Hygiene*, **100**(1): 213–221.
- Sanger, F S. Nicklen, and Coulson A,R (1977) “DNA sequencing with chain-terminating inhibitors” *Proceeding of the National Academy of Sciences of the United State of America*, **749** (12).5463-5467.
- Sani A., Bulus.T., Lawal, Mukhtar M., Abdullahi.Abubakar, Abdurrahman and Mohammad, Ahmad. (2016). Molecular Screening of Glucose-6-Phosphate Dehydrogenase Among Deficient Children Aged 0-5 Years with Plasmodium falciparum Malaria in Katsina State *Research Gate*, 46-49.
- Santana, M. S., da Rocha, M. A. F., Arcanjo, A. R. L., Sardinha, J. F. J., Alecrim, W. D., and Alecrim, M. D. G. C. (2007). Association of methemoglobinemia and glucose-6-phosphate dehydrogenase deficiency in malaria patients treated with

primaquine. *Revista da Sociedade Brasileira de Medicina Tropical Journal*, **40**(5)533-6

Santana, M. S., deLacerda M. V. G., Barbosa, M. D. G. V., Alecrim, W. D., and Alecrim, M. D. G. C. (2009). Glucose-6-phosphate dehydrogenase deficiency in an endemic area for malaria in Manaus: a cross-sectional survey in the Brazilian Amazon. *PloS one*, **4**(4), 5259.

Sati, S.A., and danwalis S.M. (2020)analysis of land use changes in kaduna north local government area, *nigeriaethiopian Journal of Environmental Studies & Management***13**(2): 126 – 137

Scott N.R., Mahmoud M.S., Mohammad S.E., Benjamin E.N., Mustafa S. A., jamal M.A., Lina, N.A., Maysaa A.S., Luzzatto L. and Prchal F.T. (2016) Favism the commonest form of severe hemolytic anemia in Palestinian children, varies in severity with three different variants of G6PD deficiency within the same community. *Blood cells, molecules and disease. Journal***60**:58-64

Segel, G. B., Hirsh, M. G., and Feig, S. A. (2002). Managing anemia in a pediatric office practice: Part 2. *Pediatrics in Review*, **23**, 111–122.

Shane N. Stone K .V. Reisig, Heather L. Saffel, and Christopher M. M. (2019) Management of Athletes With G6PD Deficiency: Does Missing an Enzyme Mean Missing More Games,*Sports Health*,**12**(2): 149–153.

Shenkutie, T.T., Nega, D. and Hailu, A. (2022). Prevalence of G6PD deficiency and distribution of its genetic variants among malaria-suspected patients visiting Metehara health centre, Eastern Ethiopia. *Malaria Journal* **21**, 260

Slusher, T. M., Zamora, T. G., Appiah, D., Stanke, J. U., Strand, M. A., Lee, B. W. and Olusanya, B. O. (2017). Burden of severe neonatal jaundice: a systematic review and meta-analysis. *Bio Medical Journal paediatrics open*, **1**(1).

Stone, S. N., Reisig, K. V., Saffel, H. L., and Miles, C. M. (2020). Management of athletes with G6PD deficiency: does missing an enzyme mean missing more

games.*Sports Health*, **12**(2), 149-153.

Sulistyaningrum, N., Arlinda, D., Hutagalung, J., Sunarno, S., Oktoberia, I. S., Handayani, S., and Chaijaroenkul, W. (2020). Prevalence of glucose 6-phosphate dehydrogenase variants in malaria-endemic areas of south central timor, eastern Indonesia. *The American Journal of Tropical Medicine and Hygiene*, **103**(2), 760.

Sumalai D., Kittipong S., Noppmats K., Supawadee Y., Kanokwan S., Kriengkrai K., and Suttiphan K. (2021). Prevalence and molecular characterization of glucose-6-phosphate dehydrogenase (G6PD) deficiency in females from previously malaria endemic regions in Northeastern Thailand and *Mediterranean Journal of Hematology and Infectious Diseases* **13** (1).

Test for glucose 6 phosphate dehydrogenase activity target product profile Geneva *World Health Organization* 2022 license: CC BY-NC-SA 3.0 IGO ISBN 978-92-4-006296-2(electronic version) **978-92-4-006297-9**

Tetard M., Milet J., Dechavanne S., Fievet N., Dorin-Semblat D., Elion J., Fairhurst R.M., Deloron P., Tuikue-N. N., and Gamain B.(2017) Heterozygous HbAC but not HbAS is associated with higher newborn birthweight among women with pregnancy-associated malaria. *Scientific Reports*.**7**(1):1414.

Thi T.N., Thinh H.T., Thanh D. T., Thi P.L., Phuoc D.N., Mai A.T., The-Hung B., Thanh V.T., and Van K.T. (2022)Molecular Characterization and Genotype-Phenotype Correlation of G6PD Mutations in Five Ethnicities of Northern Vietnam.*Anemia Journal* 2653089.

Tong, Y., Liu, B., and Zheng, H. (2020.)A novel G6PD deleterious variant identified in three families with severe glucose-6-phosphate dehydrogenase deficiency. *BMC Medical Genomics* **21**, 150.

Tong, Y., Liu, B., Zheng, H., Bao, A., Wu, Z., Gu, J., and Li, Y. (2020). A novel G6PD deleterious variant identified in three families with severe glucose-6-phosphate

dehydrogenase deficiency. *BMC Medical Genomics*, **21**(1), 1-11.

Tsuji M., Rodrigues, E. G., and Nussenzweig, R. S. (2001). Progress toward a malaria vaccine: efficient induction of protective anti-malaria immunity *Biology Chemistry Journal*. **382**:553–70.

Van Rossum H. H., de Kraa, N., Thomas, M., Holleboom, C. A., Castel, A., and van Rossum, A. P. (2015). Comparison of the direct antiglobulin test and the eluate technique for diagnosing haemolytic disease of the newborn. *Practical laboratory medicine*, **3**, 17-22.

Vitor B., Martín P.A., María J.A., Paloma B., Georgiana G., Alejandro H.D., Daniela D., Suzanne C., Elena B., and Alfonso R., Sonia A.M., Irene G.A., Carlos E.P., Jacqueline A.M., van Gaans-van D.B., Véronique C., Françoise M., Cecile A.C.M., Van E., Alex M.B., Andrea M., Jacques J.M., van D., Julia A., Alberto O. (2020). Age distribution of multiple functionally relevant subsets of CD4+ T cells in human blood using a standardized and validated 14-color EuroFlow immune monitoring tube *Frontiers in immunology* **11**, (166)

Vulliamy, T., Mason, P. and Luzzatto, L. (1992). The molecular basis of glucose-6-phosphate dehydrogenase deficiency. *Trends in Genetics* **8**(4), 138–143.

Watchko, J. F., and Maisels, M. J. (2014, November). The enigma of low bilirubin kernicterus in premature infants: why does it still occur, and is it preventable?. In *Seminars in Perinatology* **38**:7;397-(406).

WHO Working Group. (1989). Glucose-6-phosphate dehydrogenase deficiency. *Bull World Health Organization*, **67**, 601-611.

Wong, F. L., Ithnin, A., Othman, A., and Cheah, F. C. (2017). Glucose-6-phosphate dehydrogenase (G6PD) deficient infants: Enzyme activity and gene variants as risk factors for phototherapy in the first week of life. *Journal of Paediatrics*

*and Child Health*, **53**(7), 705-710.

World Health Organization. (2017). Malaria rapid diagnostic test performance: results of WHO product testing of malaria RDTs: round 7 (2016-2017).

World Health Organization. (2021). *WHO guidelines for malaria, 13 July 2021* (No. WHO/UCN/GMP/2021.01 Rev. 1). World Health Organization **1**(2)2-18

World Health Organization., (2016). *Technical Specifications Series for Submission to WHO Prequalification—Diagnostic Assessment: In Vitro Diagnostics Medical Devices to Identify Glucose-6-Phosphate Dehydrogenase (G6PD) Activity* 10665-252628.

Xu, W., Westwood, B., Bartsocas, C. S., Malcorra-Azpiazu, J. J., Indrik, K., and Beutler, E. (1995). Glucose-6 phosphate dehydrogenase mutations and haplotypes in various ethnic groups. *Blood*, **85**(1), 257-263.

Yang W.C., Tai S, Hsu C.L., Fu C.M., Chou A.K, Shao P.L., Li M.J. (2020) Reference levels for glucose-6-phosphate dehydrogenase enzyme activity in infants 7-90 days old in Taiwan. *Journal of Formosan Medical Association.*; **119**;1:1:69-74.

Yoshida, A., Beutler, E. R., and Motulsky, A. G. (1971). Human glucose-6-phosphate dehydrogenase variants. *Bulletin of the World Health Organization*, **45**(2), 243.

Yu B., Xiaoting G., Longman L.i., Junxiu H., Sifang H., Xiaoyu L., Xing C., Pan C., and Xiaobo Y., (2021). The impacts of different anticoagulants and long-term frozen storage on multiple metal concentrations in peripheral blood: a comparative study *BioMetals springer* **34** (5), 1191-1205.

Zhong, Z., Wu, H., Li, B., Li, C., Liu, Z., Yang, M., Zhang, Q., Zhong, W., and Zhao, P. (2018). Analysis of glucose-6-phosphate dehydrogenase genetic polymorphism in the Hakka population in Southern China. *Medical Science*

*Monitor*, **24**, 7316–7321.

UNDER PEER REVIEW